- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05420714
Professional Continuous Glucose Monitoring at the Parkland Diabetes Clinic
Piloting the Use of Professional Continuous Glucose Monitoring at the Parkland Diabetes Clinic
The purpose of this study is to assess whether the short-term use of professional continuous glucose monitoring (Pro-CGM) at the Parkland Diabetes Clinic in selected patients with poorly-controlled diabetes due to hyper- and/or hypoglycemia leads to improvements in patients' glycemic control within 3-6 months, subjective understanding of how food, activity, and medications affect blood sugar levels, and diabetes self-care practices. The study will be a prospective cohort study that assesses patients glycemic control and diabetes self-care practices before and 3-6 months after utilization of a Pro-CGM for 10 days. Glycemic control and diabetes self-care practices will be assessed based on hemoglobin A1c measurements and glucose data download from glucometer and Pro-CGM. A short survey will be administered at the end of the 10 days Pro-CGM use to assess whether the Pro-CGM use had a positive impact on patients' understanding of how different activities affect their blood sugar and diabetes self-care practices.
Parkland Diabetes Clinic serves an ethnically diverse, low socioeconomic patient population, the majority of whom do not have access to diabetes technology like continuous glucose monitoring. CGM measures sugar levels every 5 to 15 minutes and have been shown in clinical studies to improve glycemic control. Establishing a professional CGM program at the clinic will provide short-term access to this technology. One of the main reason for conducting this study is to determine if Pro-CGM would be a useful intervention to integrate into the clinic's routine practice in the future.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Patients of the Parkland Diabetes Clinic who meets one or more of the following criteria:
- Patients with inaccurate HgbA1c due to conditions that affect red blood cell turnover (examples include but not limited to: anemia, hemoglobinopathies, chronic kidney disease)
- Patients with suspected recurrent hypoglycemia and/or hypoglycemia unawareness
- Patients with persistently elevated HgbA1c >8% despite reported adherence to medications and lifestyle modifications and after assessment by a Certified Diabetes Care and Education Specialist (CDCES)
- Patients with inability to do frequent fingersticks for blood glucose checks due to physical limitations (examples include but not limited to: vision loss, dexterity problems)
Exclusion Criteria:
- Patients who already have their own personal continuous glucose monitoring device
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Professional CGM Trial
Participants will be asked to wear Dexcom Professional Continuous Glucose Monitoring (Pro-CGM) Device for 10 days.
They will have 2 clinic visits with a certified diabetes care and education specialist (CDCES): initial visit for placement of the Pro-CGM and final visit to review the data with CDCES and their diabetes clinic provider.
They will be asked to complete a short survey at the end of the 10 days about their experience using the Pro-CGM device and how it impacts their diabetes self-care practices.
|
Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days.
They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Average change in glycemic control 3 months after Pro-CGM use
Tidsramme: 3 months
|
Glycemic control will be assessed at baseline and 3 months after intervention by measuring hemoglobin A1c and/or obtaining 14-day average glucose from glucometer or CGM blood sugar data download.
These data are collected as part of routine diabetes care at the clinic and will be obtained by chart review.
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Average change in hypoglycemia frequency 3 months after Pro-CGM use
Tidsramme: 3 months
|
Hypoglycemia frequency will be assessed at baseline and 3 months after intervention by reviewing 14-day fingerstick glucose data from glucometer download and comparing the % of blood sugar reading <70 mg/dL at baseline and 3 months after intervention.
These data are collected as part of routine diabetes care at the clinic and will be obtained by chart review.
|
3 months
|
Average change in hyperglycemia frequency 3 months after Pro-CGM use
Tidsramme: 3 months
|
Hyperglycemia frequency will be assessed at baseline and 3 months after intervention by reviewing 14-day fingerstick glucose data from glucometer download and comparing the % of blood sugar reading >180 mg/dL at baseline and 3 months after intervention.
These data are collected as part of routine diabetes care at the clinic and will be obtained by chart review.
|
3 months
|
Average change in frequency of fingerstick blood glucose checks 3 months after Pro-CGM use
Tidsramme: 3 months
|
The frequency of fingerstick glucose checks per day will be obtained from glucometer data download, which provides the average # of blood sugar reading per day, at baseline and 3 months after intervention.
These data are collected as part of routine diabetes care at the clinic and will be obtained by chart review.
|
3 months
|
Percentage of positive patient response to the Pro-CGM Questionnaire
Tidsramme: The survey will be administered at the end of the 10 days Pro-CGM use. The percentage of positive responses will be calculated at the end of study.
|
The patients are given a questionnaire with 8 "Yes or No" questions about whether or not wearing the CGM has a positive impact on their diabetes self-care practices (diet, exercise, medication adherence, blood glucose monitoring).
The percentage of "Yes" responses for the 8 questions will be calculated.
|
The survey will be administered at the end of the 10 days Pro-CGM use. The percentage of positive responses will be calculated at the end of study.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Felona Gunawan, MD, University of Texas Southwestern Medical Center
Publikationer og nyttige links
Generelle publikationer
- Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun;9(3):203-10. doi: 10.1089/dia.2007.0205.
- Leinung M, Nardacci E, Patel N, Bettadahalli S, Paika K, Thompson S. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013 Sep;15(9):744-7. doi: 10.1089/dia.2013.0027. Epub 2013 Jun 20.
- Kesavadev J, Vigersky R, Shin J, Pillai PBS, Shankar A, Sanal G, Krishnan G, Jothydev S. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. Adv Ther. 2017 Aug;34(8):1918-1927. doi: 10.1007/s12325-017-0576-x. Epub 2017 Jun 30.
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STU-2021-1012
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsAfsluttetDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
Kliniske forsøg med Dexcom Professional Continuous Glucose Monitoring
-
University Hospital Bispebjerg and FrederiksbergZealand University Hospital; Rigshospitalet, Denmark; Steno Diabetes Center...RekrutteringDiabetes mellitus | Dysglykæmi | Perioperativ komplikation | Kredsløb; KomplikationerDanmark
-
Christian S. MeyhoffZealand University Hospital; Rigshospitalet, Denmark; Steno Diabetes Center...Ikke rekrutterer endnuEffekten af kontinuerlig glukosemonitorering hos kirurgiske patienter med diabetes. (WARD-glucose)Diabetes mellitus | Dysglykæmi | Perioperativ komplikationDanmark
-
Medical University of ViennaRekrutteringGraviditetskomplikationer | Blodsukker | Svangerskabsdiabetes | GDM | CgmØstrig
-
Peter KristensenRekrutteringDiabetes mellitus, type 2Danmark
-
Stanford UniversityAfsluttetGraviditetskomplikationerForenede Stater
-
Vanderbilt University Medical CenterRekrutteringDuchennes muskeldystrofiForenede Stater
-
Vanderbilt University Medical CenterRekrutteringDuchennes muskeldystrofiForenede Stater
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetType 2 diabetes | Slutstadie nyresygdomForenede Stater
-
Oregon Health and Science UniversityJuvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley...Afsluttet
-
Beijing Tsinghua Chang Gung HospitalThe First Affiliated Hospital of Anhui Medical University; Beijing Tiantan... og andre samarbejdspartnereRekrutteringOmfattende komplikationsindeksKina